JP2005535592A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535592A5 JP2005535592A5 JP2004505299A JP2004505299A JP2005535592A5 JP 2005535592 A5 JP2005535592 A5 JP 2005535592A5 JP 2004505299 A JP2004505299 A JP 2004505299A JP 2004505299 A JP2004505299 A JP 2004505299A JP 2005535592 A5 JP2005535592 A5 JP 2005535592A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- group
- dihydroquinoline
- oxo
- carboxylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 47
- 239000001257 hydrogen Substances 0.000 claims 47
- 125000000547 substituted alkyl group Chemical group 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 33
- 150000003839 salts Chemical class 0.000 claims 32
- 150000002431 hydrogen Chemical class 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 21
- 125000003710 aryl alkyl group Chemical group 0.000 claims 21
- 239000002671 adjuvant Substances 0.000 claims 19
- 239000003937 drug carrier Substances 0.000 claims 19
- 239000000546 pharmaceutical excipient Substances 0.000 claims 19
- 239000000651 prodrug Substances 0.000 claims 13
- 229940002612 prodrug Drugs 0.000 claims 13
- 239000012453 solvate Substances 0.000 claims 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 5
- 229910052783 alkali metal Inorganic materials 0.000 claims 4
- 150000001340 alkali metals Chemical class 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- FLFWQGUPVISINQ-UHFFFAOYSA-N 6-(1-amino-2,3-dihydroinden-1-yl)-7-chloro-1-ethyl-4-oxoquinoline-3-carboxylic acid Chemical compound C1CC2=CC=CC=C2C1(N)C1=C(Cl)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 FLFWQGUPVISINQ-UHFFFAOYSA-N 0.000 claims 3
- DSGIFDNRYKUMIS-UHFFFAOYSA-N 6-(2-amino-2,3-dihydro-1h-inden-1-yl)-7-chloro-1-ethyl-4-oxoquinoline-3-carboxylic acid Chemical compound NC1CC2=CC=CC=C2C1C1=C(Cl)C=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 DSGIFDNRYKUMIS-UHFFFAOYSA-N 0.000 claims 3
- ZTSMPSHBQSNWCI-UHFFFAOYSA-N 6-(benzylamino)-7-chloro-1-ethyl-4-oxoquinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCC1=CC=CC=C1 ZTSMPSHBQSNWCI-UHFFFAOYSA-N 0.000 claims 3
- VFGYKHXNWXHYBP-UHFFFAOYSA-N 6-[2-(4-bromophenyl)ethylamino]-7-chloro-1-ethyl-4-oxoquinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCC1=CC=C(Br)C=C1 VFGYKHXNWXHYBP-UHFFFAOYSA-N 0.000 claims 3
- HABXYYQSXXJDDR-UHFFFAOYSA-N 7-chloro-1-ethyl-4-oxo-6-(2-phenoxyethylamino)quinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCOC1=CC=CC=C1 HABXYYQSXXJDDR-UHFFFAOYSA-N 0.000 claims 3
- YJZNRUDSDUGJDM-UHFFFAOYSA-N 7-chloro-1-ethyl-4-oxo-6-(2-phenylpropylamino)quinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCC(C)C1=CC=CC=C1 YJZNRUDSDUGJDM-UHFFFAOYSA-N 0.000 claims 3
- NLTJREJJMULMPU-UHFFFAOYSA-N 7-chloro-1-ethyl-4-oxo-6-(3-phenylpropylamino)quinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCCC1=CC=CC=C1 NLTJREJJMULMPU-UHFFFAOYSA-N 0.000 claims 3
- XBZSEQLJUKDRIJ-UHFFFAOYSA-N 7-chloro-1-ethyl-4-oxo-6-(4-phenylbutylamino)quinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCCCC1=CC=CC=C1 XBZSEQLJUKDRIJ-UHFFFAOYSA-N 0.000 claims 3
- UWBJWQLFBBSLSJ-UHFFFAOYSA-N 7-chloro-1-ethyl-6-[(2-methoxy-2-phenylethyl)amino]-4-oxoquinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCC(OC)C1=CC=CC=C1 UWBJWQLFBBSLSJ-UHFFFAOYSA-N 0.000 claims 3
- UFAJYBNJKVTUMV-UHFFFAOYSA-N 7-chloro-1-ethyl-6-[2-(3-methoxyphenyl)ethylamino]-4-oxoquinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCC1=CC=CC(OC)=C1 UFAJYBNJKVTUMV-UHFFFAOYSA-N 0.000 claims 3
- JMGMXGRLMXHFPJ-UHFFFAOYSA-N 7-chloro-1-ethyl-6-[2-(4-methoxyphenyl)ethylamino]-4-oxoquinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCC1=CC=C(OC)C=C1 JMGMXGRLMXHFPJ-UHFFFAOYSA-N 0.000 claims 3
- CGZFHTHUVLPESP-UHFFFAOYSA-N 7-chloro-6-[2-(4-chlorophenyl)ethylamino]-1-ethyl-4-oxoquinoline-3-carboxylic acid Chemical compound ClC=1C=C2N(CC)C=C(C(O)=O)C(=O)C2=CC=1NCCC1=CC=C(Cl)C=C1 CGZFHTHUVLPESP-UHFFFAOYSA-N 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000036461 convulsion Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 206010022437 insomnia Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 206010029333 Neurosis Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 206010039966 Senile dementia Diseases 0.000 claims 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007278 cognition impairment Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000015238 neurotic disease Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000035882 stress Effects 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38064102P | 2002-05-14 | 2002-05-14 | |
| PCT/US2003/014948 WO2003097564A2 (en) | 2002-05-14 | 2003-05-12 | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005535592A JP2005535592A (ja) | 2005-11-24 |
| JP2005535592A5 true JP2005535592A5 (enExample) | 2006-06-29 |
| JP4532263B2 JP4532263B2 (ja) | 2010-08-25 |
Family
ID=29549994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004505299A Expired - Fee Related JP4532263B2 (ja) | 2002-05-14 | 2003-05-12 | 置換されたキノロンカルボン酸、その誘導体、作用の部位、およびその使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7355047B2 (enExample) |
| EP (1) | EP1503759B1 (enExample) |
| JP (1) | JP4532263B2 (enExample) |
| KR (1) | KR20040107525A (enExample) |
| CN (1) | CN1652784A (enExample) |
| AT (1) | ATE417613T1 (enExample) |
| AU (1) | AU2003229043B2 (enExample) |
| BR (1) | BR0309965A (enExample) |
| CA (1) | CA2484308A1 (enExample) |
| DE (1) | DE60325347D1 (enExample) |
| DK (1) | DK1503759T3 (enExample) |
| ES (1) | ES2319176T3 (enExample) |
| IL (1) | IL164734A0 (enExample) |
| MX (1) | MXPA04011156A (enExample) |
| NZ (1) | NZ536061A (enExample) |
| WO (1) | WO2003097564A2 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1503759B1 (en) * | 2002-05-14 | 2008-12-17 | The Regents Of The University Of California | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
| DE102004004971B3 (de) * | 2004-01-31 | 2005-09-15 | Aventis Pharma Deutschland Gmbh | Cycloalkyl substituierte 7-Amino-4-chinolon-3-carbonsäure-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arnzeimittel |
| US7470706B2 (en) | 2004-01-31 | 2008-12-30 | Sanofi-Aventis Deutschland Gmbh | Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments |
| US7825278B2 (en) * | 2004-05-06 | 2010-11-02 | The Regents Of The University Of California | Substituted enaminones, their derivatives and uses thereof |
| CA2881078C (en) | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US8354427B2 (en) * | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| JP4796622B2 (ja) * | 2005-04-11 | 2011-10-19 | エフ．ホフマン−ラ ロシュ アーゲー | （３，４−ジヒドロ−キナゾリン−２−イル）−インダン−１−イル−アミン |
| JP4796624B2 (ja) * | 2005-05-04 | 2011-10-19 | エフ．ホフマン−ラ ロシュ アーゲー | ５−ｈｔ受容体に作用する（３，４−ジヒドロ−キナゾリン−２−イル）−（２−アリールオキシ−エチル）−アミン類 |
| WO2007067489A1 (en) * | 2005-12-05 | 2007-06-14 | Merck & Co., Inc. | Quinolone m1 receptor positive allosteric modulators |
| WO2007075901A2 (en) * | 2005-12-24 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Quinolin- 4 - one derivatives as modulators of abc transporters |
| LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
| AU2007225088B2 (en) * | 2006-03-13 | 2012-09-13 | Kyorin Pharmaceutical Co., Ltd | Aminoquinolones as GSK-3 inhibitors |
| EP1886996A1 (en) * | 2006-08-10 | 2008-02-13 | Ferrer Internacional, S.A. | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions |
| JP2010500330A (ja) * | 2006-08-10 | 2010-01-07 | フエルレル インターナショナル，ソシエダッド アノニマ | Ｇａｂａａ受容体に対して親和性を有する１ｈ−キノリン−４−オン化合物、方法、使用及び組成物 |
| SI2074123T1 (sl) | 2006-10-16 | 2013-03-29 | Bionomics Limited | Nove anksiolitične spojine |
| US10954231B2 (en) | 2006-10-16 | 2021-03-23 | Bionomics Limited | Anxiolytic compounds |
| WO2009040377A2 (en) * | 2007-09-27 | 2009-04-02 | Ge Healthcare Limited | Imaging agents |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| JP2012506857A (ja) * | 2008-10-23 | 2012-03-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合複素環式ｍ１受容体ポジティブアロステリック調節因子 |
| SI3330255T1 (sl) | 2009-03-20 | 2021-03-31 | Vertex Pharmaceuticals Incorporated | Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi |
| US20120093917A1 (en) * | 2009-04-02 | 2012-04-19 | Robert Hromas | Metnase and intnase inhibitors and their use in treating cancer |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| EP2680842A4 (en) * | 2011-03-02 | 2014-10-29 | Bionomics Ltd | METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM |
| WO2012116415A1 (en) | 2011-03-02 | 2012-09-07 | Bionomics Limited | Novel small-molecules as therapeutics |
| CN103649086A (zh) | 2011-05-12 | 2014-03-19 | 生态学有限公司 | 制备萘啶的方法 |
| EP2819670B1 (en) | 2012-02-27 | 2026-05-20 | Vertex Pharmaceuticals Incorporated | Pharmaceutical Composition and Their Administration |
| CA2963945C (en) | 2014-10-07 | 2023-01-10 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
| CN107501107A (zh) * | 2017-09-26 | 2017-12-22 | 兰亚朝 | 喹诺酮药物的中间体合成方法 |
| CN111269131B (zh) * | 2020-03-12 | 2021-12-28 | 江苏飞宇医药科技股份有限公司 | 以三正丙胺为吸酸剂制备环丙乙酯胺化物的工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1433774A (en) * | 1973-02-26 | 1976-04-28 | Allen & Hanburys Ltd | Heterocyclic compounds apparatus for conveying articles |
| JPS5715760B2 (enExample) * | 1974-06-11 | 1982-04-01 | ||
| US4390541A (en) * | 1980-12-19 | 1983-06-28 | Lilly Industries Limited | Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease |
| US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
| MXPA01011173A (es) * | 1999-05-06 | 2002-04-24 | Neurogen Corp | 4-0x0-quinolin-3-carboxamidas sustituidas: ligandos del receptor cerebro de gaba. |
| GB0127349D0 (en) * | 2001-11-14 | 2002-01-02 | Glaxo Group Ltd | Macrolides |
| EP1503759B1 (en) * | 2002-05-14 | 2008-12-17 | The Regents Of The University Of California | Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof |
-
2003
- 2003-05-12 EP EP03726824A patent/EP1503759B1/en not_active Expired - Lifetime
- 2003-05-12 WO PCT/US2003/014948 patent/WO2003097564A2/en not_active Ceased
- 2003-05-12 MX MXPA04011156A patent/MXPA04011156A/es active IP Right Grant
- 2003-05-12 DE DE60325347T patent/DE60325347D1/de not_active Expired - Lifetime
- 2003-05-12 ES ES03726824T patent/ES2319176T3/es not_active Expired - Lifetime
- 2003-05-12 JP JP2004505299A patent/JP4532263B2/ja not_active Expired - Fee Related
- 2003-05-12 US US10/514,808 patent/US7355047B2/en not_active Expired - Fee Related
- 2003-05-12 BR BR0309965-2A patent/BR0309965A/pt not_active IP Right Cessation
- 2003-05-12 AU AU2003229043A patent/AU2003229043B2/en not_active Ceased
- 2003-05-12 NZ NZ536061A patent/NZ536061A/en unknown
- 2003-05-12 CA CA002484308A patent/CA2484308A1/en not_active Abandoned
- 2003-05-12 KR KR10-2004-7018340A patent/KR20040107525A/ko not_active Ceased
- 2003-05-12 CN CNA03810816XA patent/CN1652784A/zh active Pending
- 2003-05-12 AT AT03726824T patent/ATE417613T1/de not_active IP Right Cessation
- 2003-05-12 DK DK03726824T patent/DK1503759T3/da active
-
2004
- 2004-10-20 IL IL16473404A patent/IL164734A0/xx unknown
-
2008
- 2008-02-15 US US12/032,403 patent/US20080176897A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014526469A5 (enExample) | ||
| JP2004534816A5 (enExample) | ||
| JP2007501809A5 (enExample) | ||
| JP2020503010A5 (enExample) | ||
| JP2020503009A5 (enExample) | ||
| JP2005508349A5 (enExample) | ||
| JP2009531277A5 (enExample) | ||
| JP2008510770A5 (enExample) | ||
| JP2005528325A5 (enExample) | ||
| JP2010530881A5 (enExample) | ||
| JP2018138577A5 (enExample) | ||
| JP2022533912A5 (enExample) | ||
| JP2021105002A5 (enExample) | ||
| JP2004500426A5 (enExample) | ||
| JP2005516067A5 (enExample) | ||
| JP2011529918A5 (enExample) | ||
| RU2009138602A (ru) | Новые производные бензазепина | |
| JP2005523922A5 (enExample) | ||
| JP2020517607A5 (enExample) | ||
| JP2009538910A5 (enExample) | ||
| CA2656057A1 (en) | Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain | |
| JP2005525322A5 (enExample) | ||
| JP2012509279A5 (enExample) | ||
| JP2025509438A5 (enExample) | ||
| JP2011525185A5 (enExample) |